Vertex and CRISPR Therapeutics announce USFDA approval of Casgevy for treatment of sickle cell disease
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
Express Scripts to add Zepbound to National Preferred Formulary
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Methylene blue is a cationic thiazine dye that necessitates specialised capabilities and expertise to develop and manufacture the product
Varenicline Tablets, 0.5 mg and 1 mg are indicated for use as an aid to smoking cessation treatment.
Ivabradine Tablets, 5 mg and 7.5 mg had annual sales of USD 136.5 mn in the United States
Norgestrel and Ethinyl Estradiol Tablets USP (RLD: Lo/Ovral-28) had estimated annual sales of US $33 million in the US
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Bromfenac Ophthalmic Solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain
Subscribe To Our Newsletter & Stay Updated